G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Bevacizumab Treatment for Advanced Breast Cancer
Ricardo H. Alvarez,Valentina Guarneri,Fikri Icli,Stephen R. D. Johnston,D. Khayat,Sibylle Loibl,Miguel Martin,Christoph C. Zielinski,Pierfranco Conte,Gabriel N. Hortobagyi +9 more
TL;DR: This review outlines the most promising breast cancer studies using bevacizumab combined with traditional cytotoxic agents in advanced breast cancer and defines the vision of how the benefit of patient clinical trials should be measured.
Journal ArticleDOI
Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer.
Lajos Pusztai,Francisco J. Esteva,Massimo Cristofanilli,Mien Chie Hung,Gabriel N. Hortobagyi +4 more
TL;DR: Current clinical research with a select group of chemotherapy response modifiers, including agents that modulate signal transduction, oncogene expression and apoptosis with an emphasis on breast cancer are reviewed.
Journal ArticleDOI
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Beverly Moy,R. Bryan Rumble,Steven E. Come,Nancy E. Davidson,Angelo Di Leo,Julie R. Gralow,Gabriel N. Hortobagyi,Douglas Yee,Ian E. Smith,Mariana Chavez-MacGregor,Rita Nanda,Heather L. McArthur,Laura Spring,Katherine E. Reeder-Hayes,Kathryn J. Ruddy,Paul Unger,Shaveta Vinayak,William J. Irvin,Avan Armaghani,Michael A. Danso,Natalie R. Dickson,Sophie S. Turner,Cheryl L. Perkins,Lisa A. Carey +23 more
TL;DR: In this paper, the authors updated recommendations of the ASCO guideline on chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.
Journal ArticleDOI
Diagnostic breast imaging.
TL;DR: A systematic, highly reproducible methodology for detection, diagnosis, and assessment of findings Easy-to-follow flowcharts for the diagnostic work-up of both typical and atypical cases.
Journal ArticleDOI
A phase II study of peptichemio in advanced breast cancer
V. Hug,Gabriel N. Hortobagyi,Gabriel N. Hortobagyi,Aman U Buzdar,George R. Blumenschein,Grose We,Michael A. Burgess,Gerald P. Bodey +7 more
TL;DR: This trial showed that PTC is another alkylating agent with definite activity in the treatment of breast cancer, and showed that cross‐resistance with cyclophosphamide does not exist, at least in breast carcinoma.